Skip to main content
Download PDF

Clinical, pathological and genetic characteristics of 17 unrelated children with Alagille Syndrome

BMC Pediatrics volume 24, Article number: 532 (2024) Cite this article

Abstract

Background

Alagille syndrome (ALGS) is a multisystem genetic disorder frequently characterized by hepatic manifestations. This study analyzed the clinical, pathological, and molecular genetic features of ALGS to improve the efficiency of clinical diagnosis.

Methods

We retrospectively analyzed the clinical manifestations, pathological examination findings, and genetic testing results of 17 children diagnosed with ALGS based on the revised criteria and hospitalized at our center from January 2012 to January 2022.

Results

The clinical manifestations are as follows: Cholestasis (16/17, 94%), characteristic facies (15/17, 88%), heart disease (12/16, 75%), butterfly vertebrae (12/17, 71%) and posterior embryotoxon (7/12, 58%). Among the 15 patients who underwent liver pathology examination, 13 (87%) were found to have varying degrees of bile duct paucity. Genetic testing was performed on 15 children, and pathogenic variants of the jagged canonical Notch ligand 1 (JAG1) gene were identified in 13 individuals, including 4 novel variants. No pathogenic variant in the notch homolog 2 (NOTCH2) gene were identified, and 2 children exhibited none of the aforementioned gene pathogenic variants. The median follow-up duration was 7 years. Of the remaining 15 patients (excluding 2 lost to follow-up), 11 remained stable, 4 deteriorated, and no patient died during the follow-up period.

Conclusions

Among children diagnosed with ALGS, cholestasis stands as the most common feature. To minimize the risk of misdiagnosis, genetic testing should be performed on children exhibiting cholestasis, followed by the application of the revised diagnostic criteria for ALGS. While pharmacological therapy has shown effectiveness for ALGS patients, liver transplantation may be considered in instances of severe pruritus.

Peer Review reports

Introduction

Alagille Syndrome (ALGS) is a rare multisystem disorder with an estimated incidence rate ranging from 1 in 30,000 to 1 in 100,000 individuals [1]. It is inherited in an autosomal dominant manner in approximately 40% of patients [2]. ALGS is primarily attributed to pathogenic variants in the jagged canonical Notch ligand 1 (JAG1) and Notch Homolog 2 (NOTCH2) genes, which encode molecules involved in the NOTCH signaling pathway [3,4,5]. The severity of ALGS can range from asymptomatic presentations to fatal complications, with a mortality rate reaching up to 10% [4, 6, 7]. The clinical manifestations of ALGS are diverse, including cholestasis, characteristic facies, posterior embryotoxon, abnormal development of the heart and bones, kidney and vascular abnormalities in some patients, and liver histopathology may reveal the absence of intrahepatic bile ducts [2]. However, due to the variable expressivity of clinical manifestations among ALGS patients, some exhibit only a single typical symptom, and some are even in a subclinical state when seeking medical attention [8,9,10,11,12]. Consequently, relying on classical diagnostic criteria may lead to overlooking the diagnosis of ALGS [13, 14]. The current diagnosis primarily relies on the revised diagnostic criteria introduced in 2007 [15, 16], which incorporate genetic testing to improve diagnosis accuracy. We retrospectively analyzed the clinical data of 17 children diagnosed with ALGS at our hospital over the past 10 years, aiming to provide compelling evidence supporting the early detection of ALGS.

Materials and methods

Patients

The study enrolled 17 children diagnosed with ALGS who were admitted to the Fifth Medical Center of the PLA General Hospital from January 2012 to January 2022. ALGS diagnosis was established based on the revised criteria [15, 16], excluding children with comorbidities. Cholestasis was defined by elevated serum direct/conjugated bilirubin levels (> 1.0 mg/dL or > 17µmol/L), or by gamma-glutamyl transpeptidase (GGT) levels surpassing 3 times the upper limit of normal [17, 18]. Characteristic facies is described as an inverted triangular face, defined by a prominent forehead, deep-set eyes with hypertelorism, a straight nose with a bulbous tip, and a pointed chin [2].

Clinical data were gathered from medical records and follow-up visits. At diagnosis, demographic characteristics and clinical data were recorded, including clinical symptoms, laboratory data (liver function and lipid tests), physical examination results (growth and development condition, facial features, and indications associated with chronic hepatitis, such as jaundice, spider nevi, or palmar erythema), routine examinations (cardiac and abdominal ultrasound, chest and abdominal Computed Tomography, abdominal Magnetic Resonance Imaging, and spinal X-ray), and specialist examinations (ophthalmic slit-lamp examination). Additionally, results from liver biopsy and genetic testing were obtained. The study was ethically approved by the Ethics Committee at the Fifth Medical Center of the PLA General Hospital. All clinical information and images presented in this report were acquired with prior written consent from the patients’ parents.

Percutaneous liver pathology

Percutaneous liver biopsies were performed on 15 cases. The paraffin-embedded tissue was sectioned and stained with hematoxylin, eosin, Masson’s trichrome, cytokeratin-7 and cytokeratin-19. The histological examination was reviewed by experienced pathologists. Bile duct paucity was defined as the absence of interlobular bile ducts in at least 50% of the portal tracts within liver samples containing 10 or more portal areas [19].

Genetic variation analysis

DNA was extracted from peripheral blood, with detailed methodology outlined in the previous publications [20, 21]. Briefly, the sequenced data were then aligned with the human reference genome version 19 (hg19) using the Burrows-Wheeler Alignment (BWA) Tool (http://bio-bwa.sourceforge.net/). The Genome Analysis Toolkit (GATK) software (www.broadinstitute.org/gatk) was used to analyze single-nucleotide polymorphisms (SNPs). ANNOtation VARiants (ANNOVAR) was utilized for annotating candidate variants(annovar.openbioinformatics.org/en/latest/). MutationTaster [22], Sorting Intolerant From Tolerant (SIFT) [23, 24] and Polyphen-2 [25] programs were used to predict the potential impacts of single-nucleotide variants (SNVs). Following the American College of Medical Genetics and Genomics (ACMG) guideline [26], pathogenic variants were classified as benign, likely benign, variants of unknown clinical significance (VUS), likely pathogenic and pathogenic. The candidate causal variants identified via whole-exome sequencing (WES) were subsequently confirmed using Sanger sequencing. Co-segregation analyses were also performed within the patient’s family. Fragments covering mutated sites were amplified, purified with the Zymoclean Polymerase Chain Reaction (PCR) Purification Kit (Zymo Research, USA), and sequenced using an ABI 3730 DNA Sequencer (SeqGen, CA). Sanger sequencing data were analyzed by Chromas Lite v2.01 (Technelysium Pty Ltd., Tewantin, QLD, Australia).

Treatment and follow-up

Except for 2 patients who opted out of medication owing to their mild symptoms, the other 15 patients underwent prolonged oral therapy, which comprised of ursodeoxycholic acid, cholestyramine, bicyclic alcohol, and compound glycyrrhizin tablets, as well as various vitamin supplements. Children exhibiting severe cholestasis or pruritus underwent liver transplantation. Every three months, the children’s liver function, biochemistry, blood routine, and abdominal ultrasound were reviewed, along with regular assessments of their growth and development. Treatment adjustments were made in accordance with changes in the patients’ conditions. All patients were followed up until August 2023.

Statistical analysis

Continuous variables were shown as medians and interquartile ranges. Categorical variables were presented as counts and percentages. Statistical analysis was performed with R Foundation for Statistical Computing software (v. 4.1.3; Vienna, Austria; http://www.r-project.org/).

Results

Clinical characteristics

This study included a total of 17 participants, with 10 males and 7 females. The median age of onset among the 17 children was 2 months (range: 1-168 months), with most developing the disease within 3 months of birth. The median age at diagnosis was 5 years (range: 1–15 years).

All patients in the study exhibited liver involvement. Cholestasis was the most prevalent characteristic, affecting 94% of the patients (16/17). Characteristic facies was the second most prevalent, presenting in 88% of patients (15/17) (Fig. 1). Heart disease was identified in 75% of patients (12/16), and butterfly vertebrae were detected in 71% (12/17) (Fig. 2). The posterior embryotoxon was detected in approximately 58% of patients (7/12) assessed. Growth retardation was observed in 53% of the children (9/17), and pruritus was reported by 42% (7/17). Only Patient 8 had a relevant family history, specifically a history of ALGS in an elder brother. Abdominal MRI scans revealed cirrhosis with ascites in patients 5 and 11, which was histologically confirmed. Both patients, aged over 10 years, exhibited significant cholestasis upon admission. Detailed clinical information for each patient is provided in Table 1 and Supplementary Table 1.

Fig. 1
figure 1

Characteristic facies of Alagille syndrome in case 2: a child aged 1 year and 7 months with a prominent forehead, deep-set eyes with hypertelorism, a straight nose with a bulbous tip, and a pointed chin

Full size image
Fig. 2
figure 2

Butterfly vertebrae in case 11 (The lesions occurred in the thoracic vertebra region, as indicated by an arrow)

Full size image
Table 1 Clinical characteristics of 17 children with ALGS
Full size table

Biochemical results

Laboratory examination indicators for all patients are presented in Table 2. AST, GGT, and LAP levels were elevated in all patients. Total biliary acid (TBA) was increased in 16 patients (94%), LAP in fifteen patients (88%), alanine aminotransferase (ALT) in thirteen patients (76%), total cholesterol (TC) in thirteen patients (76%), triglycerides (TG) in twelve patients (71%), DBil in seven patients (42%), and alkaline phosphatase (ALP) levels in five patients (29%).

Table 2 Biochemical characteristics of 17 children with ALGS
Full size table

Histological results

15 children underwent liver biopsy for pathology examination, revealing intrahepatic bile duct paucity in 12 cases (Fig. 3). Mild liver inflammation and fibrosis were both present in 14 patients. The liver biopsy of one patient indicated cirrhosis (Table 3 and supplementary Table 2).

Fig. 3
figure 3

The histopathological change of liver biopsy in case 11. A: Liver cell swelling, fibrous tissue proliferation and few bile duct in the portal area (HE, original magnifi cation × 100); B: Few bile duct in the portal area (CK-7/19, original magnifi cation × 100); C: Few bile duct in the portal area (CK-7/19, original magnifi cation × 200)

Full size image
Table 3 Pathological results of liver puncture in 15 childrena with ALGS
Full size table
Table 4 Genetic traits of children with Alagille syndrome
Full size table

Genetic test results

Among the 15 individuals subjected to genetic testing, 13 carried pathogenic variants in the JAG1 gene, while none exhibited pathogenic variants in the NOTCH2 gene. No JAG1 gene pathogenic variants were detected in two patients. Thirteen distinct pathogenic variants in the JAG1 gene were identified in the 13 children harboring such variants, comprising six frameshift, three nonsense, two missense, one splice-site mutation, and one large fragment heterozygosity loss. Four novel pathogenic variants in the JAG1 gene were identified in our study. All pathogenic variants identified in our study were either previously reported or predicted to be pathogenic. The amino acid changes induced by these pathogenic variants are located at diverse positions on the JAG1 protein. Bioinformatics software was used to assess the pathogenicity of an unreported missense mutation, c.548T > A (p.I183N), which was deemed harmful by MutationTaster, SIFT, and Polyphen-2 (Table 4, Fig. 4 and Fig. S1).

Fig. 4
figure 4

The protein structure of mutation p.I183N was shown in red (PDBID:4CC0)

Full size image

Management and follow-up

After a period of treatment, most children demonstrated improved liver function test results, yet their pruritus did not experience significant relief. Liver transplantation was performed for case 8 (presenting with severe pruritus and stunted growth) and case 11 (suffering from severe cholestasis).

All patients underwent follow-up for a median duration of 7 years. During this period, 2 patients were lost to follow-up, 11 remained stable, and 4 experienced deteriorated. None of the children in the study developed liver cancer or succumbed to the disease. Apart from cases 5 and 11, who were initially diagnosed with decompensated cirrhosis, no other child progressed to this condition. Cases 8 and 11, who underwent liver transplantation, were monitored for 2 years post-surgery. Presently, both are administered tacrolimus orally as an anti-rejection measure. Although their symptoms of jaundice and pruritus resolved post-transplantation, growth and development of case 8 remained below normal levels, while case 11 exhibited postoperative anemia.

Discussion

ALGS, a multisystem disorder affecting multiple organs, was first reported by Alagille in 1969, with classical diagnostic criteria were established in 1975 [27]. The classical diagnostic criteria require histological confirmation of bile duct paucity and with a minimum of three additional characteristic symptoms [13, 14, 27]. Due to the stringency of the classical diagnostic criteria, only 12 children in our study met the criteria. Currently, the diagnosis of ALGS predominantly relies on revised criteria [15, 16] that emphasize the diagnostic significance of JAG1 gene pathogenic variants, enhancing diagnostic efficiency.

Cholestasis is widely regarded as a characteristic symptom in children with ALGS [2, 28,29,30]. In this study, 94% of patients presented with cholestasis during consultation. This percentage is comparable to the 89% incidence of cholestasis reported in the King’s College case series [31]. Bile duct paucity or hypoplasia is a key symptom of ALGS. Among the 15 patients who underwent liver pathology examination in this study, 13 (87%) patients had bile duct defects of varying degrees, a higher proportion than the 75% incidence of bile duct paucity reported by King’s College [31]. However, other studies indicate that the incidence of bile duct paucity in children with ALGS can reach up to 85% [32]. Overall, bile duct paucity is the most consistent feature of ALGS [33], and different detection rates may be related to subject age and errors in liver biopsy. To differentiate biliary atresia (BA), biliary exploration was performed on two children (cases 3 and 7) at 2 months of age. There have been reported cases where ALGS was erroneously diagnosed as biliary atresia, ultimately leading to death or liver transplantation following Kasai surgery [34, 35]. Hence, in cases of suspected biliary atresia, biliary exploration is crucial to exclude ALGS.

Characteristic facies is a well-known prominent feature of patients with ALGS, particularly those harboring pathogenic variants of the JAG1 gene [36, 37]. Characteristic facies can be identified in 80% of children with ALGS [38], while in this study, 88% of the patients exhibited this typical feature. Prompt identification of suspicious facial features in children is crucial. However, characteristic facies may not be apparent in early infancy [39, 40]. Furthermore, the use of characteristic facies in diagnosis remains controversial due to the subjectivity of facial observation and variations in observer interpretation [39]. Heart disease is the most common extrahepatic manifestation of ALGS, with an overall incidence of 94% [33]. Among these, the pulmonary artery is the most common site of anomalies, accounting for approximately 76% of all patients with cardiac anomalies [41]. In this study, approximately 75% of patients exhibited cardiac anomalies, whereas only 25% presented pulmonary artery anomalies. Although complex cardiac lesions are recognized as a significant cause of mortality in children with ALGS [32], none of the children in our follow-up study succumbed. The prevalence of butterfly vertebrae in our study was 71%, aligning with previous reports that ranged from 33–87% [42]. Most skeletal abnormalities in the studied children were predominantly found in the thoracic vertebrae, with only case 13 showing lumbar and sacral vertebrae affected. Posterior embryotoxon is the most common ocular abnormality in patients with ALGS, which usually does not affect vision and occurs in 56-95% of ALGS patients [43, 44]. Among the 12 children who underwent ophthalmic slit lamp examination in this study, 7 were found to have posterior embryotoxon, representing approximately 58% of the examined population.

Genetic testing in this study revealed a pathogenic variant detection rate of 87% for the JAG1 gene, whereas no pathogenic variant was identified in the NOTCH2 gene. These findings are consistent with the conclusions of previous studies [12]. As an important ligand of the Notch signaling pathway, changes in the structure and function of JAG1 protein significantly affect Notch signaling levels [12]. The NOTCH signaling pathway has been found to be involved in the development of multiple systems, often manifesting as multi-system symptoms in patients with ALGS [45]. However, genetic testing in this study yielded negative results for two children. This phenomenon has also been reported in previous studies [27, 46, 47], we speculate that it may be related to the fact that whole-exome sequencing technology is prone to miss deletions. Additionally, we noticed that four patients inherited their JAG1 gene pathogenic variants from their “healthy” mothers. These mothers exhibited no overt clinical symptoms during their visits, and due to limitations, liver pathology examinations were not conducted on these apparently “healthy” mothers. We speculate that the asymptomatic carriage of JAG1 gene pathogenic variants may be due to differential expression of the JAG1 gene in hepatoblasts and portal vein mesenchyme (PVM). Previous studies have suggested that the absence of Jag1 in hepatoblasts does not affect bile duct development in mice. In addition, the correlation between ALGS genotype and phenotype remains unclear, and some modifier genes are thought to impact the phenotype of patients with ALGS [48].

Ursodeoxycholic acid is currently the first-line therapy for ALGS and has been proven effective in controlling patients’ pruritus and xanthoma formation [49]. Although ursodeoxycholic acid treatment yielded positive therapeutic outcomes for these children, a subset experienced minimal relief from pruritus. To address this issue, we added choline amine as adjuvant therapy, which effectively controlled the children’s pruritus. Clinically, however, liver transplantation remains necessary for 21-31% of patients due to severe pruritus [50], with our study observing a 29% rate. While liver transplantation significantly improves patients’ original symptoms, postoperative complications and the long-term need for immunosuppressants significantly affect their quality of life, echoing findings from previous studies [51, 52]. Due to advancements in treatment modalities and improved survival rates following liver transplantation (LT), over 90% of children with ALGS now survive into adulthood [2, 29]. By the end of the follow-up, all study patients had reached adulthood with stable disease conditions. Hence, it is imperative for adult hepatologists to possess a thorough understanding of the clinical manifestations and therapeutic approaches associated with ALGS. Such knowledge is essential to address the evolving healthcare demands of ALGS patients transitioning from pediatric to adult medical care [2].

This study had several limitations. Firstly, as a retrospective, single-center study, it was constrained by a limited sample size. Secondly, the study’s subjects were exclusively hospitalized patients with relatively severe conditions, potentially introducing bias. In future studies, we plan to expand the sample size and include more outpatient cases. Lastly, all children in this study underwent whole exome sequencing for genetic testing. The limitations of this sequencing technology may result in missed detections of deletions. Furthermore, it is crucial to acknowledge the challenges posed by the homology in covering exons 1–4 of the NOTCH2 gene, which may potentially lead to their omission during exome sequencing.

Conclusion

Cholestasis is the most prevalent characteristic observed in children diagnosed with ALGS. Genetic testing should be conducted for children presenting with cholestasis, followed by the application of revised diagnostic criteria for ALGS to minimize misdiagnosis. Pharmacological therapy has proven effective for patients with ALGS, while liver transplantation may be considered in cases of severe pruritus.

Data availability

All data generated or analyzed during this study are included in this article.

Further enquiries can be directed to the corresponding author.

Abbreviations

ALGS:

Alagille Syndrome

JAG1:

Jagged Canonical Notch Ligand 1

NOTCH2:

Notch Homolog 2

GGT:

Gamma-Glutamyl Transpeptidase

CT:

Computed Tomography

MRI:

Magnetic Resonance Imaging

hg19:

human reference genome version 19

BWA:

Burrows-Wheeler Alignment

GATK:

Genome Analysis Toolkit

SNPs:

Single-Nucleotide Polymorphisms

ANNOVAR:

ANNOtation VARiants

SIFT:

Sorting Intolerant From Tolerant

SNVs:

Single-Nucleotide Variants

ACMG:

American College of Medical Genetics and Genomics

VUS:

Variants of Unknown Clinical Significance

WES:

Whole-Exome Sequencing

PCR:

Polymerase Chain Reaction

AST:

Aspartate Transaminase

LAP:

Leucine Aminopeptidase

TBA:

Total Biliary Acid

ALT:

Alanine Aminotransferase

TC:

Total Cholesterol

TG:

Triglycerides

TBil:

Total Bilirubin

DBil:

Direct Bilirubin

ALP:

Alkaline Phosphatase

References

  1. Diaz-Frias J, Kondamudi NP. Alagille Syndrome. In: StatPearls edn. Treasure Island (FL) ineligible companies. Disclosure: Noah Kondamudi declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.

  2. Ayoub MD, Bakhsh AA, Vandriel SM, Keitel V, Kamath BM. Management of adults with Alagille syndrome. Hep Intl 2023.

  3. Gilbert MA, Bauer RC, Rajagopalan R, Grochowski CM, Chao G, McEldrew D, Nassur JA, Rand EB, Krock BL, Kamath BM, et al. Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum Mutat. 2019;40(12):2197–220.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Benabed Y, Chaillou E, Denis MC, Simard G, Reynier P, Homedan C. Alagille syndrome: a case report. Ann Biol Clin. 2018;76(6):675–80.

    Google Scholar 

  5. Mašek J, Andersson ER. Jagged-mediated development and disease: mechanistic insights and therapeutic implications for Alagille syndrome. Curr Opin Cell Biol. 2024;86:102302.

    Article  PubMed  Google Scholar 

  6. Chen HL, Wu SH, Hsu SH, Liou BY, Chen HL, Chang MH. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. J Biomed Sci. 2018;25(1):75.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Mitchell E, Gilbert M, Loomes KM. Alagille Syndrome. Clin Liver Dis. 2018;22(4):625–41.

    Article  PubMed  Google Scholar 

  8. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo WL, Cochran J, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet. 1997;16(3):243–51.

    Article  PubMed  CAS  Google Scholar 

  9. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet. 2006;79(1):169–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet. 1997;16(3):235–42.

    Article  PubMed  CAS  Google Scholar 

  11. Schindler EA, Gilbert MA, Piccoli DA, Spinner NB, Krantz ID, Loomes KM. Alagille syndrome and risk for hepatocellular carcinoma: need for increased surveillance in adults with mild liver phenotypes. Am J Med Genet Part A. 2021;185(3):719–31.

    Article  PubMed  CAS  Google Scholar 

  12. Halma J, Lin HC. Alagille syndrome: understanding the genotype-phenotype relationship and its potential therapeutic impact. Expert Rev Gastroenterol Hepatol. 2023;17(9):883–92.

    Article  PubMed  CAS  Google Scholar 

  13. Alagille D, Odièvre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr. 1975;86(1):63–71.

    Article  PubMed  CAS  Google Scholar 

  14. Alagille D, Estrada A, Hadchouel M, Gautier M, Odièvre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr. 1987;110(2):195–200.

    Article  PubMed  CAS  Google Scholar 

  15. Suchy BMK, Sokol FJ, Balistreri RJ. WF: Liver disease in children. 3rd ed. edn. Cambridge: Cambridge University Press; 2007.

    Book  Google Scholar 

  16. Guru Murthy GS, Rana BS, Das A, Thapa BR, Duseja AK, Dhiman RK, Chawla YK. Alagille syndrome: a rare disease in an adolescent. Dig Dis Sci. 2012;57(11):3035–7.

    Article  PubMed  Google Scholar 

  17. Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VL, et al. Guideline for the Evaluation of Cholestatic Jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2017;64(1):154–68.

    Article  PubMed  CAS  Google Scholar 

  18. EASL Clinical Practice Guidelines. : management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.

    Article  Google Scholar 

  19. Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol. 1988;7(2):193–9.

    Article  PubMed  CAS  Google Scholar 

  20. Song F, Feng S, Shen X, Du M, Yin H, Liu R, Chen X. Next-generation sequencing revealed Disease-causing variants in two genes in a patient with combined features of spherocytosis and Antley-Bixler Syndrome with Genital anomalies and Disordered Steroidogenesis. Front Genet. 2020;11:976.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Wang X, Shen X, Fang F, Ding CH, Zhang H, Cao ZH, An DY. Phenotype-driven virtual panel is an effective method to analyze WES Data of Neurological Disease. Front Pharmacol. 2018;9:1529.

    Article  PubMed  CAS  Google Scholar 

  22. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.

    Article  PubMed  CAS  Google Scholar 

  23. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE. 2012;7(10):e46688.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinf (Oxford England). 2015;31(16):2745–7.

    CAS  Google Scholar 

  25. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Medicine: Official J Am Coll Med Genet. 2015;17(5):405–24.

    Article  Google Scholar 

  27. Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genetics: EJHG. 2012;20(3):251–7.

    Article  PubMed  CAS  Google Scholar 

  28. Chen Y, Sun M, Teng X. Clinical and genetic analysis in Chinese children with Alagille syndrome. BMC Pediatr. 2022;22(1):688.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Vandriel SM, Li LT, She H, Wang JS, Gilbert MA, Jankowska I, Czubkowski P, Gliwicz-Miedzińska D, Gonzales EM, Jacquemin E, et al. Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study. Hepatology (Baltimore MD). 2023;77(2):512–29.

    Article  PubMed  Google Scholar 

  30. Semenova N, Kamenets E, Annenkova E, Marakhonov A, Gusarova E, Demina N, Guseva D, Anisimova I, Degtyareva A, Taran N et al. Clinical characterization of Alagille Syndrome in patients with Cholestatic Liver Disease. Int J Mol Sci 2023, 24(14).

  31. Subramaniam P, Knisely A, Portmann B, Qureshi SA, Aclimandos WA, Karani JB, Baker AJ. Diagnosis of Alagille syndrome-25 years of experience at King’s College Hospital. J Pediatr Gastroenterol Nutr. 2011;52(1):84–9.

    Article  PubMed  CAS  Google Scholar 

  32. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology (Baltimore MD). 1999;29(3):822–9.

    Article  PubMed  CAS  Google Scholar 

  33. Cheng K, Rosenthal P. Diagnosis and management of Alagille and progressive familial intrahepatic cholestasis. Hepatol Commun 2023, 7(12).

  34. Fujishiro J, Suzuki K, Watanabe M, Uotani C, Takezoe T, Takamoto N, Hayashi K. Outcomes of Alagille syndrome following the Kasai operation: a systematic review and meta-analysis. Pediatr Surg Int. 2018;34(10):1073–7.

    Article  PubMed  Google Scholar 

  35. Gunadi, Kaneshiro M, Okamoto T, Sonoda M, Ogawa E, Okajima H, Uemoto S. Outcomes of liver transplantation for Alagille syndrome after Kasai portoenterostomy: Alagille Syndrome with agenesis of extrahepatic bile ducts at porta hepatis. J Pediatr Surg. 2019;54(11):2387–91.

    Article  PubMed  Google Scholar 

  36. Saleh M, Kamath BM, Chitayat D. Alagille syndrome: clinical perspectives. Application Clin Genet. 2016;9:75–82.

    Article  Google Scholar 

  37. Reynal F, Camoin A, Tardieu C, Fabre A, Blanchet I. Oral findings in children with congenital cholestatic disease: a systematic review of case reports and case series. Archives de Pediatrie: Organe Officiel de la Societe francaise de Pediatr. 2023;30(6):427–37.

    Article  Google Scholar 

  38. Kamath BM, Loomes KM, Oakey RJ, Emerick KE, Conversano T, Spinner NB, Piccoli DA, Krantz ID. Facial features in Alagille syndrome: specific or cholestasis facies? Am J Med Genet. 2002;112(2):163–70.

    Article  PubMed  Google Scholar 

  39. Yang WH, Zhang L, Xue FS, Riaz A, Zhu ZJ. Pediatric Liver transplantation for Alagille Syndrome: anesthetic evaluation and Perioperative Management. Ann Transplant. 2020;25:e924282.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Li D, Mao K, Sun J, Liu J, Zhang C. Clinical and laboratory characteristics in children with Alagille Syndrome: experience of a single Center. Int J Gen Med. 2023;16:77–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. McElhinney DB, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, Goldmuntz E. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation. 2002;106(20):2567–74.

    Article  PubMed  Google Scholar 

  42. Ayoub MD, Kamath BM. Alagille Syndrome: Diagnostic challenges and advances in management. Diagnostics (Basel Switzerland) 2020, 10(11).

  43. Rennie CA, Chowdhury S, Khan J, Rajan F, Jordan K, Lamb RJ, Vivian AJ. The prevalence and associated features of posterior embryotoxon in the general ophthalmic clinic. Eye. 2005;19(4):396–9.

    Article  PubMed  CAS  Google Scholar 

  44. Hingorani M, Nischal KK, Davies A, Bentley C, Vivian A, Baker AJ, Mieli-Vergani G, Bird AC, Aclimandos WA. Ocular abnormalities in Alagille syndrome. Ophthalmology. 1999;106(2):330–7.

    Article  PubMed  CAS  Google Scholar 

  45. Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, Chu Q. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Therapy. 2022;7(1):95.

    Article  Google Scholar 

  46. Kamath BM, Bason L, Piccoli DA, Krantz ID, Spinner NB. Consequences of JAG1 mutations. J Med Genet. 2003;40(12):891–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Gilbert MA, Spinner NB. Alagille syndrome: Genetics and Functional models. Curr Pathobiology Rep. 2017;5(3):233–41.

    Article  CAS  Google Scholar 

  48. Kohut TJ, Gilbert MA, Loomes KM. Alagille Syndrome: a focused review on clinical features, Genetics, and treatment. Semin Liver Dis. 2021;41(4):525–37.

    Article  PubMed  Google Scholar 

  49. Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr. 1998;26(1):49–55.

    PubMed  CAS  Google Scholar 

  50. Akagi K, Tanaka T, Baba S. Successful living donor liver transplantation after stent implantation in a patient with Alagille syndrome and severe bilateral pulmonary artery stenosis. Cardiol Young. 2018;28(12):1465–7.

    Article  PubMed  Google Scholar 

  51. Kamath BM, Stein P, Houwen RHJ, Verkade HJ. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver International: Official J Int Association Study Liver. 2020;40(8):1812–22.

    Article  CAS  Google Scholar 

  52. Ebel NH, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P. Health Care Resource utilization by patients with Alagille Syndrome. J Pediatr. 2023;253:144–e151141.

    Article  PubMed  Google Scholar 

  53. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South ST, Thorland EC, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Medicine: Official J Am Coll Med Genet. 2020;22(2):245–57.

    Article  Google Scholar 

  54. Jurkiewicz D, Gliwicz D, Ciara E, Gerfen J, Pelc M, Piekutowska-Abramczuk D, Kugaudo M, Chrzanowska K, Spinner NB, Krajewska-Walasek M. Spectrum of JAG1 gene mutations in Polish patients with Alagille syndrome. J Appl Genet. 2014;55(3):329–36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Crosnier C, Driancourt C, Raynaud N, Hadchouel M, Meunier-Rotival M. Fifteen novel mutations in the JAGGED1 gene of patients with Alagille syndrome. Hum Mutat. 2001;17(1):72–3.

    Article  PubMed  CAS  Google Scholar 

  56. Colliton RP, Bason L, Lu FM, Piccoli DA, Krantz ID, Spinner NB. Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients. Hum Mutat. 2001;17(2):151–2.

    Article  PubMed  CAS  Google Scholar 

  57. Warejko JK, Schueler M, Vivante A, Tan W, Daga A, Lawson JA, Braun DA, Shril S, Amann K, Somers MJG et al. Whole Exome Sequencing Reveals a Monogenic Cause of Disease in ≈ 43% of 35 Families With Midaortic Syndrome. Hypertension (Dallas, Tex: 1979) 2018, 71(4):691–699.

  58. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RK, Hua Y, Gueroussov S, Najafabadi HS, Hughes TR, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Sci (New York NY). 2015;347(6218):1254806.

    Article  Google Scholar 

  59. Dong Y, Wang J, Zhu S, Zheng H, Wang C, Zhao P. Clinical profiles and diagnostic challenges in 1158 children with rare hepatobiliary disorders. Pediatr Res. 2021;89(1):238–45.

    Article  PubMed  Google Scholar 

  60. Krantz ID, Colliton RP, Genin A, Rand EB, Li L, Piccoli DA, Spinner NB. Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families. Am J Hum Genet. 1998;62(6):1361–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Wang F, Li Y, Zhao S, Chen Z, Xu Z, Wang L, Zhang TJ, Yan J, Cao L, Wang P, et al. The utility of hierarchical genetic testing in paediatric liver disease. Liver International: Official J Int Association Study Liver. 2022;42(5):1097–108.

    Article  CAS  Google Scholar 

  62. Cho JM, Oh SH, Kim HJ, Kim JS, Kim KM, Kim GH, Yu E, Lee BH, Yoo HW. Clinical features, outcomes, and genetic analysis in Korean children with Alagille syndrome. Pediatr Int. 2015;57(4):552–7.

    Article  PubMed  CAS  Google Scholar 

  63. Heritage ML, MacMillan JC, Anderson GJ. DHPLC mutation analysis of Jagged1 (JAG1) reveals six novel mutations in Australian alagille syndrome patients. Hum Mutat. 2002;20(6):481.

    Article  PubMed  Google Scholar 

  64. Jurkiewicz D, Popowska E, Gläser C, Hansmann I, Krajewska-Walasek M. Twelve novel JAG1 gene mutations in Polish Alagille syndrome patients. Hum Mutat. 2005;25(3):321.

    Article  PubMed  Google Scholar 

  65. Lin HC, Le Hoang P, Hutchinson A, Chao G, Gerfen J, Loomes KM, Krantz I, Kamath BM, Spinner NB. Alagille syndrome in a Vietnamese cohort: mutation analysis and assessment of facial features. Am J Med Genet Part A. 2012;158a(5):1005–13.

    Article  PubMed  Google Scholar 

  66. Wang H, Xiao F, Qian Y, Wu B, Dong X, Lu Y, Cheng G, Wang L, Yan K, Yang L, et al. Genetic architecture in neonatal intensive care unit patients with congenital heart defects: a retrospective study from the China neonatal genomes project. J Med Genet. 2023;60(3):247–53.

    Article  PubMed  Google Scholar 

  67. Bauer RC, Laney AO, Smith R, Gerfen J, Morrissette JJ, Woyciechowski S, Garbarini J, Loomes KM, Krantz ID, Urban Z, et al. Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum Mutat. 2010;31(5):594–601.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Crosnier C, Driancourt C, Raynaud N, Dhorne-Pollet S, Pollet N, Bernard O, Hadchouel M, Meunier-Rotival M. Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome. Gastroenterology. 1999;116(5):1141–8.

    Article  PubMed  CAS  Google Scholar 

  69. Stranneheim H, Lagerstedt-Robinson K, Magnusson M, Kvarnung M, Nilsson D, Lesko N, Engvall M, Anderlid BM, Arnell H, Johansson CB, et al. Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. Genome Med. 2021;13(1):40.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are particularly grateful to all the people who have given us help on our article.

Funding

The capital health development project 2022-1-2182.

Author information

Author notes

  1. Jianguo Yan and Yuanzhi Huang contributed equally to this work.

Authors and Affiliations

  1. Peking University 302 Clinical Medical School, 38 Xueyuan Road, 100191, Beijing, China

    Yuanzhi Huang & Min Zhang

  2. Senior Department of Liver Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

    Jianguo Yan, Yuanzhi Huang, Lili Cao, Yi Dong, Zhiqiang Xu, Fuchuan Wang, Yinjie Gao, Danni Feng & Min Zhang

Authors
  1. Jianguo Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuanzhi Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lili Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiqiang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fuchuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yinjie Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Danni Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Min Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MZ, JGY and YZH conceived the idea and conceptualised the study. JGY and YZH collected data.JGY, YZH, ZQX, YD, FCW, YJG, LLC and DNF analyzed the data. JGY and YZH wrote the main manuscript text and repared all figures. MZ reviewed the manuscript. All authors reviewed the manuscript.

Corresponding author

Correspondence to Min Zhang.

Ethics declarations

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki (as was revised in 2013). The study was approved by Ethics Committee of The Fifth Medical Center of Chinese PLA General Hospital. We obtained written informed consent from all subjects and/or their legal guardian(s) for publication of identifying information/images.

Consent to publish

Informed consent from all subjects and/or their legal guardian(s) for publication of identifying information/images was obtained.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Supplementary Material 3

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, J., Huang, Y., Cao, L. et al. Clinical, pathological and genetic characteristics of 17 unrelated children with Alagille Syndrome. BMC Pediatr 24, 532 (2024). https://doi.org/10.1186/s12887-024-04973-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12887-024-04973-y

Keywords

BMC Pediatrics

ISSN: 1471-2431

Contact us